SkinDermic® business strategy is to partner its proprietary drug candidates with pharmaceutical, biotech or cosmetics companies for development, manufacturing and commercialization of its novel drugs.
SkinDermic® owns a pipeline of new drugs for the treatment of dermatological diseases (Acne and Acne-prone skin, Kaposi’s sarcoma, Lightening/Melasma).
The Company has 5 first-in-class, internally discovered, molecules candidates for clinical development including:
- SDA-001, SDA-002 and SDA-003, anti-inflammatory molecules developed for topical use for human inflammatory acne
- SDK-001 and SDK-002, pro-apoptotic molecules for human cutaneous Kaposi’s sarcoma lesions that act selectively in HHV8 infected cells.
- SDL-006, anti-melanogenic molecule indicated as Skin dark spot corrector and for lightening